Cure My Disease

Don't miss your cure!

 Log in / Sign up

A smarter way to choose liver cancer treatment? a new model aims to match therapy to the patient.

NCT ID NCT07109336

Disease control Sponsor: Zhongda Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study tests a decision model that aims to predict whether a person with unresectable hepatocellular carcinoma, a type of liver cancer, will benefit more from transarterial chemoembolization (TACE) alone or TACE combined with atezolizumab plus bevacizumab. Researchers will develop and validate the model using data from 236 adults who have already started first-line treatment with atezolizumab plus bevacizumab and are also eligible for TACE. The goal is to see if the model can accurately guide individualized treatment decisions and improve overall survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A decision model that guides whether patients with unresectable liver cancer receive TACE alone or combined with atezolizumab plus bevacizumab
What this could lead to
If successful, this could give doctors a reliable tool to choose the best first-line treatment for each person with unresectable liver cancer, improving survival and avoiding unnecessary procedures.
What could go wrong
The model is being tested for accuracy and may not improve outcomes in practice. The study is observational, so it cannot prove cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

236 people

The number who actually took part.

Started

Aug 2025

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Aged≥18 years * Initiated first-line Atezo+Bev. * Eligible for TACE treatment or received at least one TACE within ±2 months of Atezo+Bev initiation (before Atezo+Bev start, anytime during Atezo+Bev therapy, or after Atezo+Bev discontinuation). * Clinically or pathologically diagnosed uHCC before or at the initiation of Atezo/Bev.The evidence of being diagnosed as "unresectable" may include but is not limited to below: "Unresectable" or "advanced" directly documented in the medical records History of extrahepatic metastasis as evidenced clinically or by radiology, histology or cytology OR China Liver Cancer (CNLC) Stage IIIb * At least one visit record after the initiation of Atezo+Bev * No prior systemic therapy for HCC, especially immunotherapy * No prior locoregional therapy to the target lesion(s) * At least one measurable untreated lesion * ECOG Performance Status of 0-2 Exclusion Criteria: * • Evidence of extrahepatic spread (EHS) * Participating in interventional clinical trials. * Being a candidate for curative treatments * Any condition representing a contraindication to TACE as determined by the investigators * Active or history of autoimmune disease or immune deficiency * Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding * A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment * Evidence of bleeding diathesis or significant coagulopathy * Missing critical baseline or outcome data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - hepatocellular carcinoma

Contacts and locations

Locations

  • Zhongda hospital

    Nanjing, Jiangsu, 213003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.